440.00
+2.21(+0.50%)
Currency In USD
| Previous Close | 437.79 |
| Open | 434.3 |
| Day High | 452.3 |
| Day Low | 431.14 |
| 52-Week High | 615 |
| 52-Week Low | 265 |
| Volume | 266,626 |
| Average Volume | 341,760 |
| Market Cap | 9.99B |
| PE | -34.21 |
| EPS | -12.86 |
| Moving Average 50 Days | 523.53 |
| Moving Average 200 Days | 421.97 |
| Change | 2.21 |
If you invested $1000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, it would be worth $57,142.86 as of February 25, 2026 at a share price of $440. Whereas If you bought $1000 worth of Madrigal Pharmaceuticals, Inc. (MDGL) shares 5 years ago, it would be worth $3,575.49 as of February 25, 2026 at a share price of $440.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET. The p
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
GlobeNewswire Inc.
Feb 11, 2026 10:00 AM GMT
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra® (resmetirom) as the foundational treatmentMadrigal will develop next-generation siRN
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
GlobeNewswire Inc.
Feb 02, 2026 1:05 PM GMT
CONSHOHOCKEN, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, prior to the open of the U.S